INTRODUCTION

Deletions and duplications can result in abnormalities in chromosomal structure and function, thus leading to a wide range of congenital anomalies, such as Cri du chat syndrome, DiGeorge syndrome, etc. 

Approximately 1 in 150 live births presents chromosomal abnormalities. Although the mortality is not extremely high, survivors have severe disabilities. Even worse, there are no specific treatments for such chromosomal disorders until now. Chromosomal deletions and duplications can be prenatally detected using foetal DNA samples, which may be the best way to prevent chromosomal abnormalities.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd

Abstract

The present study aimed to estimate the clinical performance of non-invasive prenatal testing (NIPT) based on high-throughput sequencing method for the detection of foetal chromosomal deletions and duplications. A total of 6348 pregnant women receiving NIPT using high-throughput sequencing method were included in our study. They all conceived naturally, without twins, triplets or multiple births. Individuals showing abnormalities in NIPT received invasive ultrasound-guided amniocentesis for chromosomal karyotype and microarray analysis at 18-24 weeks of pregnancy.

Detection results of foetal chromosomal deletions and duplications were compared between high-throughput sequencing method and chromosomal karyotype and microarray analysis. Thirty-eight individuals were identified to show 51 chromosomal deletions/duplications via high-throughput sequencing method. In subsequent chromosomal karyotype and microarray analysis, 34 subchromosomal deletions/duplications were identified in 26 pregnant women. The observed deletions and duplications ranged from 1.05 to 17.98 Mb. Detection accuracy for these deletions and duplications was 66.7%. Twenty-one deletions and duplications were found to be correlated with the known abnormalities. NIPT based on high-throughput sequencing technique is able to identify foetal chromosomal deletions and duplications, but its sensitivity and specificity were not explored. Further progress should be made to reduce false-positive results.

Keywords

cell-free foetal DNA, chromosomal abnormalities, chromosomal deletions/duplications, high-throughput sequencing, non-invasive prenatal testing
for newborns. Conventional prenatal testing techniques include karyotyping, comparative genomic hybridization (CGH), hybridization and array-based technologies. These conventional screening methods require foetal DNA samples through invasive approaches, like amniocentesis, which may increase the risk of miscarriage and infection. Moreover, conventional testing techniques could only detect deleted and duplicated fragments of more than 10 Mb, and abnormalities with microdeletion and microduplication may be undetectable. Therefore, non-invasive prenatal genetic screening methods with high accuracy are in urgent need.

In 1997, Lo et al reported the presence of cell-free foetal DNA (cfDNA) in maternal plasma that allows the application of non-invasive prenatal testing (NIPT) in clinical practice. cfDNA in maternal plasma mainly derives from placenta, especially from the outer cytotrophoblastic layer. cfDNA shows linear correlation with chromosomal abnormalities in foetuses and is considered as the optimal proxy in NIPT. NIPT based on high-throughput sequencing technique can effectively detect large-scale genetic mutations in a short time, with high accuracy. Compared to conventional prenatal testing, high-throughput NIPT has multiple advantages. First, it causes no risk of pregnancy loss thanks to its non-invasive procedures. Second, it has been reported that the detection rate of high-throughput sequencing for trisomy 21, trisomy 18 and trisomy 13 may be up to 79%. Third, the technique is suitable for varied gestational ages, even after 23 weeks of pregnancy. In addition, the operational process is simple and automated. However, the technique is not suitable in the detection for multiple births. Moreover, its detection rate for deletions and duplications less than 10 Mb is unsatisfactory. The performance of NIPT using high-throughput sequencing technique for chromosomal deletions and duplications remained controversial.

In this study, we estimated the performance of NIPT based on high-throughput sequencing for foetal deletions and duplications.

2 | MATERIALS AND METHODS

2.1 | Study subjects

A total of 6348 eligible pregnant women were retrospectively recruited in the current study from May 2015 to January 2019. The all conceived naturally, without twins, triplets or multiple births. The included pregnant women received NIPT which was performed via high-throughput sequencing method, regardless of whether they experienced any Down syndrome examinations. Moreover, the age of the eligible subjects was over 18 years, with a pregnancy of more than 12 weeks. The pretest ultrasound scan was performed for each subject to confirm the number of foetuses and gestational age. In addition, women who had a foetus with major structural abnormalities were excluded from this study. Written informed consent was signed by each woman before inclusion. The current investigation was approved by the Ethics Committee of the Third Affiliated Hospital of Zhengzhou University.

2.2 | Blood sample and DNA extraction

Five millilitres of peripheral blood from each pregnant woman was collected into a cell-free DNA tube (Streck, Omaha, NE, USA). Then, cell-free plasma was isolated from the obtained blood samples via a two-step centrifugation method within 4 hours after collection. In brief, blood samples were first centrifuged at 1600 g for 10 minutes at 4°C, and then supernatant was transferred into a new tube and centrifuged for additional 10 minutes at 1600 g under 4°C. Final plasma supernatant was transferred to a cell-free DNA tube and then stored at −20°C for DNA extraction. Each plasma sample was thawed only once.

Cell-free DNA was extracted from plasma specimens using a Dynabeads® Viral NA DNA purification kit (Dynal, Grand Island, NY, USA), and experiment procedures were performed based on the instruction of manufacturer. DNA samples were stored at −80°C.

2.3 | DNA library construction

Firstly, cell-free DNA samples were quantified by Qubit 3.0 fluorometer (Invitrogen, Life Technologies, Carlsbad, CA, USA). No less than 10 ng DNA sample was collected from each woman, and DNA concentration was over 1.7 ng/mL. Qualified DNA samples were adopted for PCR amplification, and reaction procedures were as follows: at 99°C for 2 minutes, and 22 cycles of 99°C for 15 seconds and 60°C for 4 minutes. After primer digestion, amplification products were ligated with adaptors and purified by Agecoure AMPure SPRI beads (Beckman Coulter, Brea, CA, USA). Subsequently, the library was amplified in a volume of 52 μL solution containing 50 μL PCR amplification mixture and 2 μL primers. Then, the library was purified by magnetic beads. DNA concentration of library was estimated by Qubit 3.0 fluorometer (Invitrogen, Life Technologies).

2.4 | Sequencing template preparation and enrichment

Sequencing templates were prepared and enriched according to the standard procedures recommended by Life Technology Company. The template was prepared through emulsion PCR, which was performed using Ion temple preparation kit (Life Technologies). The reaction was carried out in a volume of 1 mL mixture including 582 μL nuclease-free water, 200 μL 5x PCR reagent mix, 100 μL 10x PCR enzyme mix, 100 μL Ion Sphere particles (ISPs) and 18 μL diluted library template. The mixture was shaken and centrifuged, and Ultra-Turrax tube drive (Life Technologies) was adopted for emulsion. Then, the mixed emulsion was transferred to 96-well plate and amplified on an ABI 2720 thermocycler (Life Technologies).

After amplification, ISP was recovered using Ion Xpress template kit (Life Technologies) following the instruction of manufacturer. Qubit 3.0 fluorometer and Ion Sphere quality control kit were
applied for particle quantification. The optimal positive ISPs for enrichment were 4%-50%. Finally, ISP enrichment was performed using Ion Xpress template kit, Ion sequencing kit and DynaBeads MyOne streptavidin C1 beads (Life Technologies), and experiments were carried out according to the guidance of manufacturer.

### 2.5 Ion torrent proton sequencing

The prepared sequencing template was annealed on PCR amplification thermocycler, and the parameters were set as follows: 95°C for 2 minutes, 37°C for 2 minutes and 25°C for storage. The annealed template was loaded and run with 200-bp single-end run configuration based on the manufacturer’s instruction (Ion sequencing kit user guide, version 2.0).

### 2.6 Bioinformatics analysis

Sequencing results were collected and analysed using VariantCaller software (Life Technologies). In comparison with human genome reference sequence (GRCh37 Sequences), chromosomal deletion and duplication were analysed. Reference genome was divided into 300 000 sliding windows which contained the same number of reads, and relative number of reads was defined as the ratio of the number of reads in an equal window to the average number of reads. The least square method was adopted to analyse linear relationship between GC content and relative number of reads. The types of foetal chromosome abnormality were predicted through dynamic threshold method and quadratic element segmentation algorithm.

### 2.7 Chromosome karyotype analysis and microarray analysis

Individuals who showed abnormalities in NIPT received ultrasound-guided amniocentesis at 18-24 weeks of pregnancy after informed consent was signed by pregnant women and their families. Amniotic fluid samples were collected from the patients for conventional G-banded cytogenetic assays and microarray analysis. Amniocytes were isolated and cultured using BIO-AMF™-2 medium (Biological Industries, Kibbutz Beit-Haemek, Israel) and Chang Medium® D (Irvine Scientific, Santa Ana, CA, USA) at 37°C with 5% CO₂ for 6-7 days. The cells at metakinesis were harvested to prepare slides according to the statements in published article.16 Then, G-band staining was performed according to the Internal System for Human Cytogenomic Nomenclature 2016.

In addition, microarray analysis was also performed for the patients. In brief, genomic DNA was extracted from amniotic fluid samples using Genomic DNA Extraction kit (QIAamp DNA Blood Mini kit; Qiagen GmBH, Hilden, Germany). DNA samples were digested, ligated and amplified via PCR method. Then, obtained products were processed according to standard procedures of Affymetrix CytoScan 750K Array analysis. The results were processed in Affymetrix GeneChip Command Console software (version 4.0) and Chromosome analysis software (Chromosome Analysis Suite version 2.1) (Affymetrix; Thermo Fisher Scientific, Inc).

| Characteristics                          | n (%)          |
|------------------------------------------|----------------|
| Ethnicity                                |                |
| Chinese Han                              | 5968 (94.01)   |
| Minorities                               | 380 (5.99)     |
| Age (y)                                  |                |
| 20-24                                    | 1056 (16.64)   |
| 25-29                                    | 2008 (31.63)   |
| 30-34                                    | 2141 (33.73)   |
| 35-39                                    | 821 (12.93)    |
| 40-44                                    | 292 (4.6)      |
| ≥45                                      | 30 (0.47)      |
| Mean age (y)                             | 32.65 ± 8.16   |
| Age range (y)                            | 21-48          |
| Number of pregnancy                      |                |
| One                                      | 3214 (50.63)   |
| Two                                      | 2347 (36.97)   |
| Three                                    | 592 (9.33)     |
| More than three                          | 195 (3.07)     |
| Gestation at NIPT                        |                |
| 12 to 13+6 wk                            | 3456 (54.44)   |
| 14 to 15+6 wk                            | 2267 (35.71)   |
| 16 to 20+6 wk                            | 501 (7.89)     |
| ≥21 wk                                   | 124 (1.95)     |
| Previous trisomy 21 pregnancy            | 56 (0.88)      |
| Previous trisomy 18 pregnancy            | 46 (0.72)      |
| Previous trisomy 13 pregnancy            | 32 (0.5)       |
| Family history of trisomy 21             | 72 (1.13)      |
| Prior Down syndrome screening test       |                |
| None                                     | 1536 (24.2)    |
| Combined first-trimester NT + biochemistry | 3671 (57.83)  |
| First-trimester NT (other ultrasound markers) only | 986 (15.53) |
| First-trimester biochemistry only        | 60 (0.95)      |
| Second-trimester biochemistry only       | 60 (0.95)      |
| Other tests, or more than one test       | 35 (0.55)      |
| Result of prior screening tests          |                |
| High risk                                | 956 (19.87)    |
| Low risk                                 | 3179 (66.06)   |
| Result not available at time of NIPT     | 577 (11.99)    |

Abbreviations: NIPT, non-invasive prenatal testing.
3 | RESULTS

3.1 Baseline characteristics of the study population

A total of 6348 pregnant women undergoing NIPT using high-throughput sequencing method were included in our study. All of the eligible cases were Chinese, and 94.01% of them were Han population. The average age of the included cases was 32.65 ± 8.16 years, with an age range of 21-48 years. 50.63% of subjects were pregnant for the first time, when 36.97% of individuals were for the second time. The median gestational age at NIPT was 14.23 weeks, and 54.44% of the participants received NIPT at 12-13 weeks of gestation. Fifty-six individuals (0.88%) had the history of trisomy 21 pregnancy, 46 cases (0.72%) had been affected by trisomy 18 at pregnancy, and 32 (0.5%) cases had previously underwent trisomy 13 pregnancies. Family history of trisomy 21 was observed in 72 (1.13%) cases. Approximate 75.8% of cases received screening test before NIPT. Meanwhile, 956 (19.87%) cases were confirmed at high risk, according to prior screening test, low risk was proposed for 3179 (66.06%) cases, while 577 (11.99%) individuals had no available data at the time of NIPT. Detailed information of the included subjects was summarized in Table 1.

3.2 Overall results of NIPT

The results of NIPT based on high-throughput sequencing method were available for all of the included patients. As displayed in Figure 1, 6094 (96.00%) patients were normal, while the rest 254 patients showed chromosomal abnormalities or suspected abnormalities, accounting for 4.0% of whole cases. Common aneuploidy was observed...
| Patient no. | Deletion/duplication | Chromosome | Size (Mb) | NIPT | Chromosome karyotype and microarray analysis | Syndrome annotation |
|------------|----------------------|------------|-----------|------|---------------------------------------------|---------------------|
| 1          | Deletion             | Chr1       | 4.07      | 832 398-4 658 333 | 814 245-4 882 747 | Unknown |
| 2          | Deletion             | Chr11      | 13.6      | 121 100 200-136 623 102 | 121 302 918-134 937 328 | Systemic retardation, cardiac dysplasia, respiratory distress and other pathogenic mutations |
| 3          | Duplication          | Chr5       | 2.62      | 24 632 136-27 255 789 | 24 412 210-27 452 145 | Unknown |
| 4          | Deletion             | Chr14      | 2.45      | 40 542 267-43 246 317 | 40 908 224-43 356 102 | Unknown |
| 5          | Deletion             | Chr16      | 1.25      | 14 756 175-16 201 100 | 14 856 202-16 107 118 | Neurocognitive disorder Susceptibility locus |
| 6          | Duplication          | Chr15      | 5.58      | 20 000 120-27 365 100 | 20 527 768-26 109 968 | Prader-Willi syndrome (type 2) |
| 7          | Duplication          | Chr13      | 6.00      | 19 400 000-25 896 725 | 19 436 286-25 437 825 | Pathogenic mutations |
| 8          | Duplication          | Chr9       | 12.99     | 310 100 000-320 786 500 | 300 261 257-313 256 123 | Unknown |
| 9          | Deletion             | Chr22      | 2.58      | 18 900 000-21 514 100 | 18 919 900-21 498 520 | DiGeorge syndrome |
| 10         | Deletion             | Chr5       | 1.40      | 250 892 900-1 620 500 | 254 652-1 658 566 | Cri du Chat syndrome |
| 11         | Deletion             | Chr15      | 4.88      | 21 410 200-26 340 000 | 21 321 794-26 205 055 | Prader-Willi/Angelman syndrome |
| 12         | Duplication          | Chr13      | 3.58      | 24 521 100-28 320 000 | 24 768 204-28 346 964 | Unclear clinical significance, benign mutation tendency |
| 13         | Deletion             | Chr21      | 2.32      | 44 782 200-46 912 100 | 44 565 059-46 880 878 | Unknown |
| 14         | Duplication          | Chr11      | 17.98     | 117 000 000-135 100 500 | 117 124 000-135 109 200 | Jacobsen syndrome |
| 15         | Duplication          | Chr17      | 4.24      | 16 426 210-20 668 010 | 16 429 920-20 667 174 | Smith-Magenis syndrome |
| 16         | Deletion             | Chr16      | 4.86      | 46 200-4 9827 900 | 46 271-4 904 686 | Rubinstein-Taybi syndrome |
| 17         | Deletion             | Chr6       | 2.06      | 168 756 200-170 897 102 | 168 832 500-170 896 037 | Dysplasia of brain structure |
| 18         | Duplication          | Chr17      | 1.41      | 72 360 200-73 800 641 | 72 364 514-77 777 326 | Cardiovascular malformations |
| 19         | Deletion             | ChrY       | 3.82      | 6 688 000-10 510 512 | 6 688 691-10 511 314 | Unknown |
| 20         | Duplication          | Chr2       | 14.71     | 161 423 256-176 131 678 | 161 423 992-176 132 164 | Unknown |
| 21         | Deletion             | Chr4       | 9.18      | 61 550-8 237 698 | 61 552-9 237 101 | Wol-Hirschhorn syndrome |
| 22         | Duplication          | Chr12      | 11.23     | 45 000-11 279 000 | 45 001-11 278 012 | Unknown |

(Continues)
in 216 patients (3.40%), while chromosomal deletion/duplication was observed in 38 subjects, accounting for 0.59% of whole cases. Among those with chromosomal aneuploidy, 91 (1.43%) showed trisomy 21, 13 (0.2%) had trisomy 18, and 6 (0.09%) had trisomy 13. Monosomy X was observed in 25 cases (0.39%), triple X syndrome was observed in five individuals (0.08%), and four cases (0.06%) exhibited Klinefelter syndrome. Furthermore, 34 individuals showed rare autosomal trisomies, accounting for 0.53% of whole cases (Figure 2).

3.3 | Detective performance of NIPT based on high-throughput sequencing method for chromosomal deletions and duplications

In our study population, 38 individuals were identified to have 51 chromosomal deletions/duplications, according to NIPT with high-throughput sequencing method, and all of them received subsequent invasive amniocentesis for chromosome karyotype and microarray analysis. Of them, 11 had more than one copy number variation (CNV). Thirty-four subchromosomal deletions/duplications were identified in 26 pregnant women using the methods of chromosome karyotype and microarray analysis. Of them, seven had more than one CNV. The detection accuracy was 66.7% (34/51).

Comparison results between NIPT and amniocentesis detection were summarized in Table 2. Thirty-four subchromosomal deletions and duplications were identified, and their sizes ranged from 1.05 to 17.98 Mb. No deletions/duplications less than 1 Mb were observed. Twenty-one deletions and duplications could be annotated by the known abnormalities, accounting for 61.8% (21/34).

In addition, 17 abnormalities in 12 cases were misdiagnosed in NIPT, and the false-positive rate was 33.3%. Detailed descriptions for false-positive results were listed in Table 3. The size of these deletions/duplications ranged from 0.50 to 4.37 Mb, and the major of them were less than 1.5 Mb.

4 | DISCUSSION

Foetal chromosomal deletions and duplications are major reasons for developmental delay and intellectual disability.17 Golden standards for the detection of chromosomal abnormalities are chromosome karyotype or microarray assay using amniocentesis, which obviously increase the risk of miscarriage and infection.18 With the discovery of cffDNA in pregnant women, NIPT using high-throughput sequencing method is widely adopted for clinical detection of chromosomal deletions and duplications. The technique shows high diagnostic accuracy for trisomy 21, 18 and 13.18 NIPT based on cffDNA has been recommended as a highly accurate approach for pregnant women with high risk of foetal aneuploidy by the American College of Obstetricians and Gynaecologists and the Society for Maternal-Fetal Medicine science 2011.19 However, there are no adequate clinical data to support the clinical application of NIPT for the detection of chromosomal deletions and duplications. The present study was designed to estimate
diagnostic performance of NIPT using high-throughput sequencing for foetal chromosomal deletions and duplications. Analysis results demonstrated that 66.7% of chromosomal deletions and duplications detected by NIPT using high-throughput sequencing could be verified by chromosome karyotype and microarray analysis. The observed CNVs ranged from 1.05 to 17.98 Mb. For abnormalities less than 1.5 Mb, false-positive rate was high. The size of deleted and duplicated CNVs was the major determinant of detective accuracy of high-throughput sequencing method.

Non-invasive prenatal testing based on high-throughput sequencing is widely used for pregnant women with high risk of chromosomal abnormalities. However, for deletions and duplications less than 10 Mb, its accuracy is relatively low. Recently, a number of studies have been devoted to improve diagnostic accuracy of NIPT for chromosomal deletions and duplications. Jensen et al reported that when genomic coverage became fourfold, which was approximately 20-fold over that of standard aneuploidy detection, deletion with 3 Mb could also be detected. The study carried out by Zhao et al demonstrated that high-throughput sequencing method for the detection of microdeletion/microduplication (3-40 Mb) might achieve 94.4% sensitivity and 99.4% specificity through improving statistical methods. Rampasek et al designed a probabilistic Hidden Markov model which combined the imbalance of allelic ratios at SNP positions, parental genotypes to phase nearby SNPs and coverage depth. In simulation experiments, about 40% of CNVs with 50-400 kb could be detected under a foetal DNA concentration of 13%. Taken together, foetal DNA concentration, the size of deletion and duplication fragments, statistical methods and coverage depth are key factors for detection accuracy of high-throughput sequencing for foetal chromosomal deletions and duplications.

In the current study, NIPT based on high-throughput sequencing technique was performed for 6348 eligible pregnant women. 4.0% of pregnant women showed chromosomal abnormalities or suspected abnormalities according to NIPT detection, while chromosomal deletions and duplications were observed in 38 patients. Invasive amniocentesis was performed for these patients. After chromosome karyotype and microarray analysis, 26 patients were identified to have 34 chromosomal deletions and duplications. The detection accuracy was 66.7%. The detected CNVs ranged from 1.05 to 17.98 Mb, and no CNVs less than 1 Mb were observed. Furthermore, among misdiagnosed CNVs by sequencing

### Table 3: The false-positive results of NIPT

| Patient no. | Deletion/duplication | Chromosome | Size (Mb) | NIPT results |
|-------------|----------------------|------------|-----------|--------------|
| 1           | Duplication          | Chr19      | 0.54      | 327 273-863 300 |
| 2           | Deletion             | Chr16      | 0.52      | 29 673 900-30 197 412 |
| 3           | Duplication          | Chr22      | 0.91      | 22 069 900-22 980 200 |
| 4           | Deletion             | Chr7       | 0.46      | 64 612 879-65 148 399 |
|             | Deletion             | Chr3       | 0.83      | 27 300-853 200 |
| 5           | Deletion             | Chr1       | 1.17      | 736 537-1 910 067 |
|             | Deletion             | Chr1       | 1.20      | 54 987 800-56 191 192 |
|             | Duplication          | Chr4       | 1.10      | 15 700 256-16 800 235 |
| 6           | Duplication          | Chr22      | 1.99      | 18 980 800-20 970 900 |
| 7           | Deletion             | Chr6       | 1.08      | 16 920 770-17 998 800 |
| 8           | Duplication          | Chr13      | 1.24      | 10 109 720-11 348 912 |
|             | Deletion             | Chr11      | 1.00      | 15 698 700-16 700 941 |
| 9           | Deletion             | Chr18      | 0.57      | 52 690 900-53 256 090 |
|             | Deletion             | Chr5       | 0.73      | 2 096 900-2 800 317 |
| 10          | Duplication          | ChrY       | 4.37      | 6 568 900-10 876 200 |
| 11          | Duplication          | Chr2       | 0.50      | 89 015 800-89 512 200 |
| 12          | Deletion             | Chr17      | 1.17      | 72 370 765-73 545 200 |

NIPT, non-invasive prenatal testing.
method, their size ranged from 0.50 to 4.37 Mb, and the majority of them were less than 1.5 Mb. NIPT based on high-throughput sequencing technique showed lower accuracy for chromosomal microdeletions and microduplications, showing a high false-positive rate. Several reasons might be responsible for such phenomenon. First, the size of deleted and duplicated CNVs was relatively small. Second, foetal DNA concentration might be not high enough. Third, the detected abnormalities might be maternal ones. In the study of Yin et al.\textsuperscript{26} 63.6% of false-positive results were caused by deletions/duplications present in maternal DNA. In addition, sequencing depth and bioinformatics analysis methods required further optimization. The study carried out by Yin et al.\textsuperscript{26} reported that with a sequencing depth up to 10 million reads, the sensitivity of sequencing method could achieve 94.5% among abnormalities more than 1 Mb.

It was worth noting that only 61.8% of deletions and duplications identified in our study were correlated with the known abnormalities. Many abnormalities might be normal inherited mutations, without clinical significance. With the developments of sequencing technique and the accumulation of clinical researches, expended databases may explain those unknown abnormalities. Thus, doctors should spend time on explaining relevant test results to patients. In addition, several limitation of NIPT based on high-throughput sequencing technique should be stated. Firstly, high costs limit its wide application in clinical practice. Secondly, the performance of NIPT for twins remained unclear.\textsuperscript{27} Besides, limited by current genome function, a certain proportion of NIPT results were inconclusive.\textsuperscript{28} Additionally, in our study only individuals showing abnormalities in NIPT received chromosome karyotype analysis and microarray analysis, considering invasive procedures of amniocentesis and reported low negative rate of NIPT. Individuals who might be misdiagnosed in NIPT did not experience chromosome karyotype analysis, and false-negative rate of NIPT was not calculated. Therefore, much more progress should be made to translate NIPT results in clinical practice.

In conclusion, NIPT based on high-throughput sequencing technique is able to identify foetal chromosomal deletions and duplications. However, due to the relatively low foetal DNA concentration, small abnormal fragments and limited sequencing depth, its false-positive rate may be high.

CONFLICT OF INTEREST
The authors have no conflicts of interest to disclose.

AUTHOR CONTRIBUTIONS
Yueli Wu: Conceptualization (equal); Data curation (equal). Linlin Zhang: Conceptualization (equal); Data curation (equal). Hong Lv: Formal analysis (equal); Funding acquisition (equal). Ying Li: Resources (equal); Writing-review & editing (equal). Chongyang Zhu: Formal analysis (equal); Resources (equal); Writing-review & editing (equal). Weifang Tian: Methodology (equal); Writing-original draft (equal). Ling Zhao: Conceptualization (equal); Writing-original draft (equal).

DATA AVAILABILITY STATEMENT
All data generated or analysed during this study are included in this article.

REFERENCES
1. Goldenberg P. An update on common chromosome microdeletion and microduplication syndromes. Pediatri Annu. 2018;47:e198-e203.
2. Espirito Santo LD, Moreira LM, Riegel M. Cri-Du-Chat syndrome: clinical profile and chromosomal microarray analysis in six patients. Biomed Res Int. 2016;2016:5467083.
3. McDonald-McGinn DM, Sullivan KE, Marino B, et al. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015;1:15071.
4. Bianchi DW, Chudova D, Sehnert AJ, et al. Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA. 2015;314:162-169.
5. Carlson LM, Vora NL. Prenatal diagnosis: screening and diagnostic tools. Obstet Gynecol Clin North Am. 2017;44:245-256.
6. Phadke SR, Puri RD, Ranganath P. Prenatal screening for genetic disorders: suggested guidelines for the Indian Scenario. Indian J Med Res. 2017;146:689-699.
7. Cuckle H, Maymon R. Development of prenatal screening – a historical overview. Semin Perinatol. 2016;40:12-22.
8. Pos O, Budis J, Szemes T. Recent trends in prenatal genetic screening and testing. F1000Res. 2019;8:764.
9. Levy B, Wapner R. Prenatal diagnosis by chromosomal microarray analysis. Fertil Steril. 2018;109:201-212.
10. Lo YM, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350:485-487.
11. Hui L. Noninvasive prenatal testing for aneuploidy using cell-free DNA – new implications for maternal health. Obstet Med. 2016;9:148-152.
12. Peng XL, Jiang P. Bioinformatics approaches for fetal DNA fraction estimation in noninvasive prenatal testing. Int J Mol Sci. 2017;18:453.
13. Abou Tayoun AN, Krock B, Spinner NB. Sequencing-based diagnostics for pediatric genetic diseases: progress and potential. Expert Rev Mol Diagn. 2016;16:987-999.
14. Kim S, Jung H, Han SH, et al. Comparison of two high-throughput semiconductor chip sequencing platforms in noninvasive prenatal testing for Down syndrome in early pregnancy. BMC Med Genomics. 2016;9:22.
15. Zhang J, Zhang B. Second-generation non-invasive high-throughput DNA sequencing technology in the screening of Down’s syndrome in advanced maternal age women. Biomed Rep. 2016;4:715-718.
16. Zhang L, Ren M, Song G, et al. Prenatal diagnosis of sex chromosomal inversion, translocation and deletion. Mol Med Rep. 2018;17:2811-2816.
17. Capalbo A, Rienzi L, Ubaldi FM. Diagnosis and clinical management of duplications and deletions. Fertil Steril. 2017;107:12-18.
18. Koumbaris G, Kypri E, Tsangaras K, et al. Cell-free DNA analysis of targeted genomic regions in maternal plasma for non-invasive prenatal testing of trisomy 21, trisomy 18, trisomy 13, and fetal sex. Clin Chem. 2016;62:848-855.
19. Committee opinion summary no. 640: cell-free DNA screening for fetal aneuploidy. Obstet Gynecol. 2015;126:691-692.
20. Jensen TJ, Dzakula Z, Deciu C, van den Boom D, Ehrich M. Detection of microdeletion 22q11.2 in a fetus by next-generation sequencing of maternal plasma. Clin Chem. 2012;58:1148-1151.
21. Zhao C, Tynan J, Ehrich M, et al. Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. Clin Chem. 2015;61:608-616.
22. Rampasek K, Arbabi A, Brudno M. Probabilistic method for detecting copy number variation in a fetal genome using maternal plasma sequencing. Bioinformatics. 2014;30:212-2128.

ORCID
Linlin Zhang https://orcid.org/0000-0002-3721-3857
23. Babu R, Van Dyke DL, Bhattacharya S, et al. A rapid and reliable chromosome analysis method for products of conception using interphase nuclei. *Mol Genet Genomic Med.* 2018;6:370-381.

24. Neofytou MC, Tsangaras K, Kypri E, et al. Targeted capture enrichment assay for non-invasive prenatal testing of large and small size sub-chromosomal deletions and duplications. *PLoS One.* 2017;12:e0171319.

25. Breveglieri G, D’Aversa E, Finotti A, Borgatti M. Non-invasive prenatal testing using fetal DNA. *Mol Diagn Ther.* 2019;23:291-299.

26. Yin AH, Peng CF, Zhao X, et al. Noninvasive detection of fetal sub-chromosomal abnormalities by semiconductor sequencing of maternal plasma DNA. *Proc Natl Acad Sci USA.* 2015;112:14670-14675.

27. Gil MM, Galeva S, Jani J, et al. Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis. *Ultrasound Obstet Gynecol.* 2019;53:734-742.

28. Suciu ID, Toader OD, Galeva S, Pop L. Non-invasive prenatal testing beyond trisomies. *J Med Life.* 2019;12:221-224.

How to cite this article: Wu Y, Zhang L, Lv H, et al. Applying high-throughput sequencing to identify and evaluate foetal chromosomal deletion and duplication. *J Cell Mol Med.* 2020;24:9936–9944. [https://doi.org/10.1111/jcmm.15593](https://doi.org/10.1111/jcmm.15593)